Series: The T Files — Series 3: “The Injection Dark Ages"
Subtitle: 50 years of yo-yo shots, hormonal roller coasters, and the pharmacology nobody warned you about
Post: 5 of 5
Tags: TRT adherence, injection discontinuation, patient experience, transdermal testosterone, delivery system development, 1990 WHO consensus, injection burden
Word Count: ~1,100
In clinical research, there is a metric called “discontinuation rate.” It is the percentage of patients who stop a treatment before the study ends — or, in the real-world context, before they achieve the long-term outcomes the treatment is designed to produce.
For injectable testosterone therapy, the discontinuation numbers told a story the field was reluctant to fully confront. Patients were starting TRT and stopping it — not because it didn’t work, but because the experience of receiving it was, for a significant portion of them, simply untenable.
Understanding why men quit injections in year one requires putting together everything from the previous posts in this series: the pharmacokinetic rollercoaster, the mood volatility, the injection site pain, the frequency burden, and a 1990 consensus statement that identified the problem precisely. Put them all together, and what emerges is a picture of a therapy that worked pharmacologically but failed experientially — and how that failure drove the development of everything that came next.
The Reasons, Documented
Injectable TRT’s adherence problem was not mysterious. Patients and clinicians articulated the reasons clearly. They cluster into four categories.
1. Injection site pain and inflammation
Oil-based intramuscular injections are not comfortable. Testosterone enanthate in sesame oil, testosterone cypionate in cottonseed oil, testosterone undecanoate in castor oil — all of them require large-bore needles, deep intramuscular insertion, and the slow deposition of an oil suspension into muscle tissue. The result is predictable: local inflammation, tenderness at the site that can last several days, and the kind of muscle soreness that is more intrusive than it sounds when it occurs every one to four weeks for the foreseeable future.
Patients who self-inject — which becomes the reality for most long-term TRT patients, since going to a clinic monthly is itself a burden — develop a personal relationship with injection technique and site rotation that many find progressively more aversive over time. The gluteal muscles, the standard target, are only so large. Scar tissue can form. Sites that once tolerated injections well begin to respond with more pronounced inflammation.
2. Emotional volatility from pharmacokinetic cycling
As documented in Post 3 of this series, the peak-and-trough pharmacokinetics of injectable testosterone produced predictable mood effects: elevated and sometimes aggressive in the supratherapeutic phase, flat and depressive in the subtherapeutic phase. For men who were prescribed TRT partly to address low mood, fatigue, and reduced wellbeing, cycling through a predictable monthly period of subtherapeutic depression was particularly demoralizing.
The formulation-specific adverse effect documented in testosterone enanthate’s package insert — “fluctuation in mood/libido” — is a clinical description of what many patients experienced as a significant quality-of-life problem. When a treatment makes you feel worse for a predictable portion of every month, discontinuation is a rational response.
3. Frequency burden
Even at the most favorable dosing intervals (every two to four weeks for enanthate and cypionate), injection-based TRT imposes a maintenance schedule that touches the patient regularly, permanently, and irreversibly as long as treatment continues. For the subset of patients who could self-inject, this meant maintaining a supply of injectable testosterone, syringes, needles, and alcohol swabs, and performing the injection procedure on schedule. For patients who relied on clinic administration, it meant recurring appointments.
This is not insurmountable, but it is relentless. Lifestyle events — travel, illness, work disruption, family obligations — all require planning around the injection schedule. Over months and years, the cumulative burden of this maintenance erodes adherence for a meaningful segment of patients.
4. The gap between expected and experienced benefit
TRT injections worked — but they worked unevenly. Patients were often counseled to expect improved energy, libido, mood, and body composition. Some of these effects took months to fully manifest. In the meantime, patients were experiencing injection discomfort, mood swings tied to the pharmacokinetic cycle, and the grinding routine of the injection schedule. When early benefits were unclear or inconsistent, the cost-benefit calculation tilted toward stopping.
The 1990 Consensus: The Official Recognition
The WHO/NIH/FDA workshop in 1990 — convened to evaluate hormonal male contraception but producing findings directly relevant to TRT — concluded formally that the primary goal of testosterone replacement therapy was to restore stable, physiological serum testosterone levels. And that no available preparation, including the gold-standard injectables, was consistently achieving this.
This was not an obscure academic finding. It was a formal policy consensus by the major regulatory and research bodies in the field, published in 1990, stating that the standard of care was pharmacokinetically inadequate. The 1990 consensus was, in retrospect, the turning point — the moment when the field officially acknowledged that the injection era’s limitations were structural, not fixable by tweaking dosing intervals.
The door was open for a fundamentally different approach to delivery.
What Patient Departure Built
The combination of documented adherence failures and the 1990 consensus created the conditions for a different kind of investment in testosterone delivery research.
The key insight was that what injectable testosterone failed to provide — stable, continuous serum testosterone — was exactly what transdermal delivery could theoretically offer. If testosterone could be absorbed continuously through the skin rather than released in a bolus from a muscle depot, the pharmacokinetic peaks and troughs might be eliminated entirely.
The first transdermal system — a scrotal testosterone patch — had actually been developed in the 1980s, partly in recognition of this principle. The scrotal patch produced surprisingly good pharmacokinetics: serum levels that more closely mimicked the body’s natural circadian testosterone production, without the extreme peaks. But it came with its own problems, which we’ll examine in the next series.
Subsequent transdermal development — non-scrotal patches, gels, solutions — was driven substantially by the clinical failure of injections to serve patients well over long-term use. The FDA approvals of Androderm (1995), AndroGel (2000), and subsequent gel products were not academic exercises. They were the market’s response to a generation of patients who had tried injections and decided, in large numbers, that there had to be something better.
The Dark Ages in Retrospect
Series 3 of The T Files has covered fifty-plus years of injectable testosterone. Propionate’s every-three-days nightmare. Enanthate’s fifty-year reign and its rollercoaster pharmacokinetics. Testosterone undecanoate’s REMS-triggering adverse effect profile. And now, the adherence data that quantified what patients had been signaling all along.
The injection era was not a failure — it produced real clinical benefit for millions of men who would otherwise have had nothing. But it was an era marked by a fundamental mismatch between what the therapy needed to achieve (stable physiological testosterone) and what the available delivery systems could provide (episodic, fluctuating hormone exposure with meaningful patient burden).
The field recognized the problem in 1990. The transdermal solutions that addressed it arrived in the years that followed. Whether they fully solved the problem — or just exchanged one set of difficulties for another — is what Series 4 is about.
Up next in Series 4 — “Gels, Patches & the Skin Transfer Disaster": The transdermal era promised to solve the injection rollercoaster. It delivered on pharmacokinetics in ways the injections never could. It also introduced new challenges nobody had anticipated — including a problem with men accidentally hormonating their families. We start where transdermal testosterone began: a small, scrotal, hair-clipping-required patch from the 1980s that worked surprisingly well and was then essentially abandoned.
